z-logo
open-access-imgOpen Access
COMPARISON OF OVULATION INDUCTION LETROZOLE AND CLOMIPHENE CITRATE IN SUBFERTILE WOMEN WITH POLYCYSTIC OVARIAN SYNDROME
Author(s) -
Amna Shafiq,
Rabiya Akbar,
Uzma Urooj,
Sadaf Zohra,
Shazia Afzal,
Madiha Tanveer
Publication year - 2021
Publication title -
pakistan armed forces medical journal
Language(s) - English
Resource type - Journals
eISSN - 2411-8842
pISSN - 0030-9648
DOI - 10.51253/pafmj.v71i5.6554
Subject(s) - medicine , letrozole , ovulation induction , ovulation , polycystic ovary , gynecology , infertility , menstruation , anovulation , endocrinology , hormone , pregnancy , tamoxifen , obesity , insulin resistance , biology , cancer , breast cancer , genetics
Objective: To compare the ovulation induction of letrozole and clomiphene citrate in sub-fertile women with polycystic ovarian syndrome. Study Design: Quasi experimental study. Place and Duration of Study: Combined Military Hospital Rawalpindi, from Jun 2018 to Aug 2019. Methodology: A total of 116 married sub-fertile women with polycystic ovarian syndrome, 16-40 years of age were included. Patients with previous surgery related to genital tract, hypothyroidism and chronic renal failure were excluded. Letrozole 5.0mg daily from Day 5-9 of menstruation was prescribed to group A women and clomiphene citrate 100 mg daily from Day 5-9 of menses was given to group B women. Results: In group A and in group B, mean age was 29.78 ± 4.71 years and 29.95 ± 4.22 years respectively. Most of the patients 59 (50.86%) were between 18-30 years of age. Mean duration since marriage was 4.23 ± 1.42 years. Mean body mass index was 29.71 ± 2.65 kg/m2. Frequency of ovulation of clomiphene citrate and letrozole in sub-fertile women with polycystic ovaries was 28 (42.28%) versus 42 (72.41%) respectively (p-value=0.008). Conclusion: This study concluded that ovulation induction of letrozole is better than clomiphene citrate in sub-fertile women with polycystic ovarian syndrome.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here